Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study
Léopoldine Lapierre, Lucie Laemmel, Emilie Bérard, Lucie Rigolot et autres
Azacitidine-venetoclax (AZA-VEN) has become a standard treatment in older or chemotherapy-ineligible AML patients. While the registration trial showed a median overall survival (OS) of 14.7 months, most real-world studies have not reproduced this result. We analyzed treatment patterns, adverse events, responses and …
fr (code pays fourni par la source)
0 citations
Clinical Lymphoma Myeloma & Leukemia